Canadian-born Patheon to return to public ownership
Patheon, a provider of outsourced pharmaceutical development and manufacturing services that was founded in Canada in 1974, has filed with the U.S. Securities and Exchange Commission to launch an initial public offering. The terms of the offering have not yet been determined. Last year, Patheon was taken private by U.S. private equity firm JLL Partners, a backer of the company since 2007, and Dutch food and chemicals group Royal DSM. The deal valued the business at US$1.4 billion. Patheon was listed on the Toronto Stock Exchange until March 2014.
8 June 2015•2 mins read
